Neurology Daily Report: 01/24/2024

A multicentre, randomised, double-blind, placebo-controlled, phase 2 study (LEGATO-HD, NCT02215616, EudraCT, 2014-000418-75) conducted across ten countries investigated the effect of laquinimod in 352 adults with Huntington's disease and found that laquinimod did not show a significant effect on motor symptoms assessed by the UHDRS-TMS, but significantly reduced caudate volume loss compared with placebo at week 52 (1).

Reference

Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF; LEGATO-HD Study Group. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Neurol. 2024 Jan 24:S1474-4422(23)00454-4. doi: 10.1016/S1474-4422(23)00454-4. Epub ahead of print. PMID: 38280392.